« Previous Release PDF
TransEnterix, Inc. Announces Proposed Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (OTCBB:TRXCD), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. TransEnterix plans to use the net proceeds from this offering for research and development, sales and marketing, and commercialization related to its SurgiBotTM system, working capital and other general corporate purposes.
Stifel and RBC Capital Markets are acting as the joint book-running managers and Ladenburg Thalmann and Raymond James are acting co-managers for the offering.
This offering will be made pursuant to the $100 million shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC") on January 8, 2014, which has become effective by rule of the SEC. A preliminary prospectus supplement and accompanying prospec